topic

1427 Evaluating MHC-II antigen presentation in vivo to identify targets for immunotherapy
Andrew Weeden, Anika Ali, Victoria Izumi, Bin Fang, Emma Sanders, William Rideout, John Koomen, Paul Stewart, Tyler Jacks, Alex M Jaeger

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A1588; DOI: 10.1136/jitc-2023-SITC2023.1427
1428 Characteristics and a novel clinical prognostic assessment of hepatitis B virus-related follicular lymphoma
Yuwei Deng, Jianli Ma, Xiaosan Zhang, Lihong Liu, Xianhuo Wang, Hongtao Song, Zirong Zhang, Caili Liu, Huilai Zhang, Qingyuan Zhang

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A1589-A1591; DOI: 10.1136/jitc-2023-SITC2023.1428
1429 Application of ICTIS to currently recruiting clinical trials: a novel scoring system to assess the inclusivity of advanced non-small-cell lung cancer immunotherapy trials
Kira Nguyen, Ashley Wei, Wint Yan Aung, Nicole Spinelli, Nagashree Seetharamu

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A1592; DOI: 10.1136/jitc-2023-SITC2023.1429
1430 Development of ICTIS: a novel scoring system for the inclusivity of advanced non-small-cell lung cancer immunotherapy clinical trials
Ashley Wei, Nagashree Seetharamu, Wint Yan Aung, Kira Nguyen

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A1593; DOI: 10.1136/jitc-2023-SITC2023.1430
1431 Developing an FDA-qualified drug development tool, the membrane proteome array, for specificity testing of antibodies and CAR-T cell therapies
Tabb Sullivan, Michael Phelan, Diana Norden, Talia Marano, Carmen Navia, Rachel Fong, Amrita Singh, Benjamin Doranz

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A1594; DOI: 10.1136/jitc-2023-SITC2023.1431
1432 Cancer-associated fibroblasts metabolic targeting overcomes T-cell exclusion and chemoresistance
Marina Broz, Emily Ko, Kristin Ishaya, Jinfen Xiao, Marco DeSimone, Xen Ping Hoi, Roberta Piras, Basia Gala, Fernando HG Tessaro, Sandra Orsulic, Bonnie Balzer, Keith Syson Chan, Jlenia Guarnerio

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A1595; DOI: 10.1136/jitc-2023-SITC2023.1432
1433 Targeting peptidyl-prolyl isomerase Pin1 to modulate cancer-associated fibroblast phenotype and TGF-beta signaling
Melvyn Chow, Morgan O’Shea, Doga Tasdemir, Hanna Starobinets, Kristin Brown, Catherine Sabatos-Peyton, Emily Corse, Sebastian Hayes, Krista Goodman

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A1596; DOI: 10.1136/jitc-2023-SITC2023.1433
1434 TGFβ-dependent LRRC15⁺ myofibroblasts dictate the tumor fibroblast setpoint to promote cancer immunotherapy resistance
Akshay Krishnamurty, Justin Shyer, Minh Thai, Vineela Gandham, Patricia Pacheco-Sanchez, Yan Qu, Beatrice Breart, Justin Elstrott, Rachana Pradhan, Matthew Buechler, Cecile Chalouni, James Ziai, Soren Muller, Shannon Turley

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A1597; DOI: 10.1136/jitc-2023-SITC2023.1434
1435 Interleukin-8 activates fibroblast and could act as a potential combinational immune-stroma therapy target
Neel Nissen, Morten A Karsdal, Nicholas Willumsen

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A1598; DOI: 10.1136/jitc-2023-SITC2023.1435
1436 Targeting stromal cell sialylation to overcome tumour-induced immunosuppressive effects on NK cells in colorectal cancer
Aoise O’Neill, Hannah Egan, Oliver Treacy, Aisling Hogan, Sean Hynes, Aideen E Ryan

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A1599; DOI: 10.1136/jitc-2023-SITC2023.1436

Main menu

topic

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

topic

Pages